Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
October 29, 2024 at 08:01 am EDT
Share
Harmony Biosciences Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported net income was USD 46.09 million compared to USD 38.46 million a year ago. Basic earnings per share from continuing operations was USD 0.81 compared to USD 0.64 a year ago. Diluted earnings per share from continuing operations was USD 0.79 compared to USD 0.63 a year ago.
For the nine months, net income was USD 96.02 million compared to USD 102.25 million a year ago. Basic earnings per share from continuing operations was USD 1.69 compared to USD 1.71 a year ago. Diluted earnings per share from continuing operations was USD 1.66 compared to USD 1.68 a year ago.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
HARMONY BIOSCIENCES HOLDINGS, INC. 
